Owners, management and financials
CVR: 44308622
DKK -341,305
Gross profit
Net result: DKK -268,417
Resistance Oncology ApS (100%)
CVR · view owners
Nils Aage Brünner, Kasper Pasternak Jørgensen
CVR · view management
Active
Founded 15 September 2023
CVR · view overview
2 employees
Annual report 2025 · average
Owner registered: Resistance Oncology ApS
CVR · 19/08/2025
View the full event history
Linker Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2023. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Nils Aage Brünner and Kasper Pasternak Jørgensen. The company is owned by Resistance Oncology ApS. According to the 2025 annual report, the company had an average of 2 employees. In 2025, the company reported a gross profit of DKK -341,305 and a net result of DKK -268,417. Equity in the 2025 report amounted to DKK 57,244.
Udvikle og kommercialisere pharmaceutiske produkter.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -341K | -268K | 107K | 57K | 2 |
Compared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of Linker Pharmaceuticals ApS is 44308622.
Linker Pharmaceuticals ApS is owned by Resistance Oncology ApS.
The management of Linker Pharmaceuticals ApS consists of Nils Aage Brünner and Kasper Pasternak Jørgensen.
In 2025, Linker Pharmaceuticals ApS reported a gross profit of DKK -341,305.
Linker Pharmaceuticals ApS had an average of 2 employees in the 2025 financial year according to the annual report.
Linker Pharmaceuticals ApS was founded on 15 September 2023.
Claim this page to add your logo and social links. Free to get started.
Contact info changed: new email: [email protected] (September 10, 2026).
Linker Pharmaceuticals ApS has published its annual report for 2025. Gross profit came to DKK -341,305, and the net result was DKK -268,417.
Contact info changed: new email: [email protected] (January 12, 2026).
As of August 19, 2025, Resistance Oncology ApS is registered as an owner of Linker Pharmaceuticals ApS with an ownership share of 100%.
Linker Pharmaceuticals ApS has published its interim report for the period September 15, 2023 to December 31, 2024.
As of September 15, 2023, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Linker Pharmaceuticals ApS.
As of September 15, 2023, Nils Aage Brünner is registered as adm. dir. of Linker Pharmaceuticals ApS.
As of September 15, 2023, Kasper Pasternak Jørgensen is registered as director of Linker Pharmaceuticals ApS.
Linker Pharmaceuticals ApS was founded on September 15, 2023.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Companies in the same industry and area
CVR 45984842
CVR 33871902
CVR 37033308
CVR 34498288
CVR 37007617
